SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-17-054979
Filing Date
2017-08-31
Accepted
2017-08-31 17:22:08
Documents
4
Period of Report
2017-08-31
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a17-21218_18k.htm 8-K 30902
2 EX-10.1 a17-21218_1ex10d1.htm EX-10.1 100676
3 EX-99.1 a17-21218_1ex99d1.htm EX-99.1 15364
4 GRAPHIC g212181mmi001.jpg GRAPHIC 2590
  Complete submission text file 0001104659-17-054979.txt   152022
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 171064003
SIC: 2834 Pharmaceutical Preparations